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Abstract In this study, we give the proof of concept for
a method to determine binding constants of compounds
in solution. By implementing a technique based on
magnetic beads with a microfluidic device for segmented
flow generation, we demonstrate, for individual droplets,
fast, robust and complete separation of the magnetic
beads. The beads are used as a carrier for one binding
partner and hence, any bound molecule is separated
likewise, while the segmentation into small microdroplets
ensures fast mixing, and opens future prospects for
droplet-wise analysis of drug candidate libraries. We
employ the method for characterization of drug–protein
binding, here warfarin to human serum albumin. The
approach lays the basis for a microfluidic droplet-based
screening device aimed at investigating the interactions
of drugs with specific targets including enzymes and
cells. Furthermore, the continuous method could be
employed for various applications, such as binding
assays, kinetic studies, and single cell analysis, in which
rapid removal of a reactive component is required.
Keywords Microfluidics . Digital microfluidics . Droplet
splitting .Magnetic beads . Serum albumin .Warfarin .
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Introduction
Pharmacokinetic studies focus on the fate of a drug after
administration to a patient. Various aspects such as the
absorption, distribution, metabolism, and excretion
(ADME) properties of the drug influence its efficiency.
The absorption and distribution of a drug depend signifi-
cantly on the extent and kinetics of its interactions with
specific components of the organism such as proteins and
other biomacromolecules or lipid membranes. In particular,
serum albumin, one of the most abundant proteins in the
blood [1], binds reversibly to an incredible variety of
ligands and drugs. In fact, the extensive understanding of
the albumin-binding behavior of a particular therapeutic
agent is important for its ADME properties [2].
Recently, increasing attention has been paid to apply
superparamagnetic iron oxide micro- or nanoparticles (mag-
netic beads, MBs) for binding assays [3, 4] including the
characterization of ligand–serum albumin interactions [5].
The increasing number of commercially available magnetic
beads with different surface groups gives further opportunity
to extend the applications in the fields of biochemistry and
biotechnology [6–8]. However, conventional liquid handling
devices suffer from the inability to study fast kinetics, which
often restricts the applications of MB-based assays [9].
On the other hand, miniaturized systems based on
microfluidic technology designed to carry out experiments
in continuous flow have received increasing interest.
Traditional bottlenecks in workup and purifications are
addressed with the promising prospect to perform all
required steps in a single device, thereby reducing sample
consumption and reaction/workup time, while reliability
and reproducibility is enhanced [10, 11].
Microfluidic devices facilitate the handling of small liquid
volumes, most impressively shown in the realization of
segmented flow, in which homogeneous droplets with
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volumes of pL to nL are injected into an immiscible carrier
fluid [12–14]. Each droplet, typically an aqueous fluid
embedded in a hydrophobic carrier solution, corresponds to
an individual microreactor, with enhanced mixing and heat
transfer performances compared to large-scale reactors. Vari-
ous functional modules for microfluidic droplet generation,
splitting, fusion, and droplet analysis have been presented in
the past and applied for numerous applications such as kinetic
investigations, crystallization, and single cell analysis [11, 15–
18]. These droplet microfluidic approaches have a great
potential for continuous screening applications in the drug
discovery, development, and testing process [19–22].
The implementation of microfluidic technology with the
manipulation of magnetic beads has been shown for numerous
applications [23–25]. However, only few studies exist, where
magnetic beads were used for concentration or separation of
bound analytes. In these examples, droplets were manipulated
on a surface by means of electrowetting on dielectrics, which
is certainly a powerful technique yet not suitable for
continuous, high-throughput droplet manipulation [26, 27].
With the final goal to develop a microfluidic device
dedicated to reveal the ADME properties of a drug, we
introduce here a simple, continuous and robust method to
determine the binding mechanisms and kinetics of a ligand
to a protein. The key idea of our device is the introduction
of magnetic beads, coated with the target protein, into
microdroplets. Such microreactors are completely sur-
rounded by the carrier, which prevents non-specific
interactions with the surfaces of the microchip. The
magnetic beads and the binding partner are introduced into
the droplets and the reaction equilibrium of binding and
dissociation events is reached. Finally, the droplets are
approaching a T-junction, where they are symmetrically
split into two droplets of equal volume. Placing a magnet
next to one of the two outlet channels results in selective
separation of the beads into one of the daughter droplets
(Fig. 1). The affinity (binding) constant can be derived from
the concentration ratio of the ligand molecules in the two
daughter droplets. In order to demonstrate the functioning
of the device, we determine the affinity constant KA of
warfarin, an anticoagulant drug, to human serum albumin
(HSA) that is immobilized on the surface of magnetic beads
(HSA_MBs). We used radio-labeled 14C-warfarin to deter-
mine the concentration before and after splitting, and
validate the results with the conventional bulk method.
Experimental
Chip fabrication
The master form of the microfluidic devices was made from
a silicon wafer coated with the negative photoresist SU-
8 that was structured by using standard photolithographic
techniques [28]. The final microdevices were made of the
elastomer poly(dimethylsiloxane) (PDMS, Sylgard 184,
Dow Corning) by molding from the master form. For this,
PDMS oligomer and curing agent were mixed at a ratio of
10:1 (w/w), degassed for a few minutes in a desiccator,
poured over the master to form a thin layer that was cured
at 100 °C for a few minutes. A neodymium N45 magnet 5×
1.5×1 mm, nickel coated (Q-05-1.5-01-N, Supermagnete,
Switzerland) was positioned on the PDMS microchip
(magnetic poles are directing to top and bottom side of
the chip) and another portion of degassed PDMS was
poured over the thin layer and the magnet to form a second
layer of about 0.8 cm. After further curing at 100 °C for
several minutes, the microchip was removed from the
Fig. 1 a Scheme of the method (not to scale). Magnetic beads coated
with human serum albumin (HSA_MBs) and the drug (warfarin) are
injected into a stream of oil to form microdroplets. Daughter droplets
are formed at the T-junction with identical volume, but unequal
content, while exposed asymmetrically to a magnetic field. Measuring
the free and total (bound+free) warfarin concentrations ([W]FREE and
[W]TOTAL) in the outlets finally enables the determination of the
association constant. b Photograph of the microdevice (with a one
Euro coin (back side) for comparison)
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master form, and 1.5-mm holes were punched for fluidic
access. A cleaning process including ethanol ultrasonica-
tion, deionized water and nitrogen washing was used to
remove PDMS. The channels had a height of 50 μm and
widths ranging between 50 and 200 μm. The structured
PDMS devices were assembled with glass cover slides
(24×40 mm, Menzel) by bonding after treatment in an
oxygen plasma. The microfluidic device was positioned on
an inverted microscope (Olympus IX 71) for video analysis
by means of a charge-coupled device camera (EMCCD
DV-887, Andor).
Mineral oil (4% w/w Span 80, SIGMA) was chosen as
the carrier phase and injected into the device by an
external syringe pump (neMESYS, Cetoni, Germany)
equipped with 1 mL plastic syringes, connected via
polyethylene tubing to the inlets of the microchip.
Alternative carrier oils (e.g., fluorinated oils or silicone
oils) could be used depending on the lipophilicity of
analytes in order to prevent the partitioning between
aqueous and organic phase [29, 30].
Preparation of human serum albumin magnetic beads
(HSA_MBs)
Amine-terminated MBs (McMag 1 μm, Bioclone) were
used for the immobilization of HSA (A9511, Sigma)
according to the previously described method [31]. Briefly,
50 mg of MBs were washed three times with 3 mL
coupling buffer (10 mM pyridine, pH 5.5) in a 4 mL
reaction tube. After the washing procedure, the MBs were
resuspended in 2 mL of 5% glutaraldehyde and gently
shaken for 3 h. Next, the supernatant was removed and the
MBs were washed three times in 3 mL of coupling buffer.
A solution of 10 mg HSA in 1 mL of coupling buffer was
added to the MBs and gently shaken for 24 h. After the
coupling procedure, the supernatant was removed and 4 mL
of the reaction stop buffer (1 M glycine, pH 8.0) was added
and gently rotated for 30 min. The supernatant was
removed and the MBs were washed three times and stored
in 1 mL 10 mM PBS buffer, pH 7.4. The Sigma protein
quantification kit (77371, Sigma) was employed to measure
the amount of HSA immobilized on the magnetic beads,
which resulted in 24.8±10.7 μg of HSA/mg of MBs. Per
HSA molecule immobilized on a magnetic bead, we
assumed 2.8 binding sites [5].
Preparation of fluorescently labeled magnetic beads
One milligram of streptavidinidated dynabeads, MyOne
(Invitrogen) were washed three times and resuspended in
1 mL PBS buffer. Then 5 μl of a stock solution of
biotinylated fluorescein (Sigma) in DMSO was added to the
beads to a final concentration of 1.5 mM. After 30 min
incubation with gentle agitation, the beads were washed
three times and resuspended in 1 mL PBS buffer.
Warfarin binding studies to HSA_MBs in a microdevice
In order to perform the microchip-based determination of
the affinity constant we mixed the drug (warfarin) and the
ligand (HSA) to allow the chemical equilibrium to be
reached before injection into the device. This procedure,
instead of the mixing into the droplets, allows control
bench-experiments to be performed on the same samples
(see below) however, different chip designs are available
for on-chip mixing [19, 20]. Just before starting the
experiment, 3 mL solution of about 100 nM radio-labeled
14C-warfarin (CFA449, Amersham) in 10 mM PBS buffer
(pH 7.4) was added to 10 mg of protein-coated beads.
Then, the solution was gently shaken for 1 h. Next, 300 μL
of the working solution were loaded into a 1-mL syringe,
connected to the microchip and injected into the carrier
phase using a T-junction geometry (Fig. 2a) [32]. Syringe
pumps were used to control flow rates; 2 μl/min for the
aqueous phase and 1 μl/min for the oil phase typically
resulted in 30 drops/s.
After formation, the droplets were split into two small
volume copies (Fig. 2b and Movie S1). While the liquid
phase was symmetrically split, the MBs were selectively
directed to the channel positioned on the side of the
neodymium magnet. The volume of the beads was
calculated to be 0.2% of the total volume of the droplet,
thus, it was considered negligible. The outlets were
connected to tubings thus allowing the emulsions to be
collected into two tubes.
Next, the tubes were vigorously shaken in order to
resuspend the water and 100 μL of each tube aliquot was
transferred into scintillation vials (566740, Beckman).
Then, 3 mL of liquid scintillation counting cocktail
(Ultima Gold, Packard) were added to each vial. The
amount of radio-labeled warfarin in the two samples
was measured with a scintillation counter (LS6800,
Beckman).
In order to provide control experiments, the concen-
trations of free and bound warfarin were measured with a
bulk method [5]. The tube containing the working solution
was vigorously shaken and 100 μL of the magnetic beads
suspension were transferred into a scintillation vial. Then,
the tube was placed into the magnetic separator (Imagnet,
BD Biosciences) for 3 min, thus an aliquot of 100 μL of the
supernatant was transferred into a scintillation vial. The
amount of warfarin in the two vials was quantified as
described above. Control experiments performed with
protein-free MBs revealed a negligible binding of warfarin
to the MBs, which is in accordance with previously
published results [5].
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Results and discussion
Droplets are formed by introducing warfarin and bead
suspension into a stream of mineral oil. At this channel
section, the beads are not affected by the magnetic field and
they usually remain inside the microdroplets. Only occa-
sionally, the loss of a bead into the mineral oil can be
observed.
The key feature of the microdevice is the withdrawal of
magnetic beads during droplet splitting from one of the
daughter droplets. We achieved this by placing a small
magnet in close proximity to one of the microchannel
outlets. As can be seen in Fig. 2, the beads (here labeled
with fluorescein) are already concentrated within one side
of the droplet just before splitting. We confirmed the
movement of the beads and hence, the mixing inside the
droplet, by fluorescence correlation spectroscopy (SI
Fig. 1), which is a method that allows determining flow
velocities in microfluidic channels [20]. The correlation
curves reveal two velocities, the slower velocity corre-
sponds to the speed of the droplets, and the faster velocity
can be assigned to the movement of the beads inside the
droplets. Once the droplets are exposed to the magnetic
field, the autocorrelation function reflects the speed of the
droplets only.
Frequently, over 95% of magnetic beads were collected
into the outlet that is close to the magnet (see Fig. 2d and
Movie S1, Electronic Supplementary Material), for the bead
concentration of 3.3 mg/mL that was used for the experi-
ments (corresponding to 5.6×108 beads/mL). Since the
droplet volume was around 1.25 nL, each droplet contained
about 700 beads. For lower bead concentrations (<200
beads per droplet, i.e., <1 mg/mL), we even observed 100%
separation efficiency, i.e., complete withdrawal of beads
into one daughter droplet (SI, movie). In general, the
method is very robust over a large range of conditions and
does not need careful adjustment. A reduced efficiency of
the bead separation was only observed for a weak magnetic
field (the magnet was placed far away from the micro-
device). High flow rates (above 5 μL/min) and very high
bead concentrations (50 mg/mL) also reduced the perfor-
mance and in these cases, we observed cross-contamination,
i.e., beads were released from a droplet and uptaken by the
next droplet. Additional experiments with bigger beads (i.e.
2.8 μm diameter instead of 1 μm) were performed, however,
the experiments were limited by the settling and adsorption
to the bottom of the channel resulting in a reduced amount
of the beads inside the droplets (data not shown).
Next, the binding of warfarin to immobilized HSA_MBs
was investigated. After successful immobilization of HSA
Fig. 2 Microscope images of
droplets containing fluores-
cently labeled magnetic beads.
a, b After formation of the
droplets, beads are circulating
inside the microdroplet. c Once
the beads are exposed to a
magnetic field, the beads accu-
mulate on one side of the drop-
let. The image demonstrates
how fast this accumulation
occurs. d Splitting of droplets
into daughter droplets of equal
volume at a T-junction. The
beads are exclusively withdrawn
to one side. Note the clustering
of fluorescent beads just before
the splitting at the front and the
middle section of the droplet, as
well as the formation of bead
chains after splitting into the
direction of the magnetic field,
which are typical observations
(scale bars 100 μm)
Table 1 Comparison of measured and reported warfarin–HSA
association constant, KA
Association constant KA×10
−5(M−1) Reference
4.74±0.867 (±2.84)a This work, on-chip method
4.93±0.371 (±2.46)a This work, bulk method
2.10±0.2 Ref. [37]
6.26±0.7 Ref. [5]
aMean of three independent experiments±standard deviation. The value in
brackets includes the error for loading of the beads with HSA. For
comparison, the error as calculated in [5] is given as well, i.e., excluding
the error for bead–HSA loading
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onto the MBs, the beads were incubated with the warfarin
solution and an aliquot was injected into the microchip to
generate a mono-disperse water-in-oil emulsion. Then, the
drops were split into two small volume copies isolating the
MBs from free warfarin solution. The warfarin concentrations
in the droplets of either side were determined and the
association constant can be derived as follows (see also Fig. 1):
KA ¼ W HSA MBs½ W½ FREE HSA MBs½ FREE
ð1Þ
where [W_HSA_MBs] is the concentration of warfarin
bound to HSA_MBs, [W]FREE is the concentration of free
warfarin and [HSA_MBs]FREE is the concentration of the
free binding sites of HSA bound to the MBs, all
concentrations for equilibrium conditions. Since the
experimental conditions guaranteed that the concentration
of the binding sites (3.35×10−6 M) is much greater than
the total warfarin concentration (i.e., around 1×10−7 M)
we can assume that [HSA_MBs]FREE≈[HSA_MBs]TOTAL.
The concentration of bound warfarin, [W_HSA_MBs],
can be derived as follows:
W HSA MBs½  ¼ W½ TOTAL  W½ FREE ð2Þ
In our experiments [W]FREE and [W]TOTAL equal the
concentration of warfarin measured after droplet splitting
in the droplet fraction without magnetic beads and with
magnetic beads, respectively, and are determined by the
scintillation counter.
The analysis of the two outlets revealed the concentra-
tion ratio of [W_HSA_MB]/[W]FREE=1.59±0.291, inde-
pendent of the initially injected concentrations. Together
with the concentration of [HSA_MBs]TOTAL=3.35 μM and
according Eq. (1), KA was (4.74±2.84)×10
5 M−1. It has to
be noted that the large standard deviation on the experi-
mental data of KA is mainly due to the variation of HSA
concentration loaded on the beads off-chip (see “Experi-
mental” section), i.e., before introduction into the droplets
(without considering this starting error, the standard
deviation is 0.867 M−1, see Table 1). The method was then
benchmarked using a previously known bulk assay (see
“Experimental” section). The analysis of the same samples
revealed [W_HSA_MB]/[W]FREE=1.66±0.125. Thus, KA,
was (4.93±2.46)×105 M−1. The results are listed in Table 1.
Our results prove that the microfluidic approach can be
reliably employed to determine the warfarin–HSA affinity.
While similar investigations of other drugs is straightfor-
ward, including competition experiments and displacement
studies, an improved detection scheme allowing analysis of
individual droplets, e.g., by fluorescence or MS [33–35]
and the implementation of electromagnets on the chip [36]
will expand the usability of this approach. Further develop-
ments that allow the complete separation of the magnetic
beads from the droplet (similar to washing steps in a bulk
process) would enable to directly discriminate between
bound and unbound drug and hence, would expand the
possibilities for binding constant determination.
Conclusions
In summary, the fast and reliable characterization of the
warfarin–human serum albumin-binding process was in-
vestigated implementing a magnetic beads technique with a
microfluidic device for segmented flow. The approach can
be regarded as a versatile tool for microfluidic droplet
generation, and is most promising in combination with
other channel geometries and manipulation modules. The
fully continuous method could be employed for various
applications, including binding assays, kinetic studies and
single cell analysis, in which the fast and complete removal
of a reactive component is required. The method can be
easily implemented into a modular device with further
functionalities as required for pharmacokinetic (ADME)
studies. We envision that transfer of drug candidate libraries
into microdroplet reactors and the possibility of droplet-
wise detection will reveal the full potential of the approach
for drug discovery and testing studies.
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